Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-F: Roll-Over Study for Participants Completing a Previous Benralizumab Study
NCT07444567Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 14
01
Overview
A Phase 3 trial of benralizumab in asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), sponsored by AstraZeneca. Started Jul 2026; status: recruiting.
02
Drugs
benralizumab
03
Conditions
asthmaeosinophilic granulomatosis with polyangiitis (EGPA)hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT07444567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444567.